Skip to contentX
Xenetic Biosciences, Inc.
X
XBIOXenetic Biosciences, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$486.97K$486.97Kderived+46.4% vs Q4 2021 Net Income-$1.48M-$1.48MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenetic Biosciences, Inc. · CIK 1534525 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,563,328N/M Operating Cash Flowderived-$750,907N/M Margins · derivedOperating margin-321.0%+242.4 pt vs Q4 2021
Net margin-304.4%+249.3 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 22, 2023 · 81 d after period end